Cancers are diseases in which abnormal cells divide uncontrollably and can invade nearby tissues or spread to other parts of the body. Cancer can arise in almost any tissue or organ and encompasses many distinct disease types.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
BridgeBio shares rose 2.10% to $69.41 after Phase 3 FORTIFY interim data for oral BBP-418 in LGMD2I/R9 showed broad efficacy and placebo-matched safety. The company plans a U.S. FDA filing in H1 2026.
Zentalis selected a 400 mg once-daily, 5-days-on/2-days-off azenosertib regimen for Cyclin E1-positive platinum-resistant ovarian cancer after a DENALI Phase 2 interim analysis. The regimen is planned for DENALI and ASPENOVA as the company pursues a potential accelerated approval pathway.
Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Researchers developed pancreatic-targeted lipid nanoparticles (AH-LNP) that enable precise mRNA delivery to the pancreas through capsule-filter-mediated accumulation. The platform demonstrated efficacy in genome editing and cancer immunotherapy across multiple animal models including non-human primates.
PDS Biotechnology adopted an amended protocol for its Phase 3 VERSATILE-003 trial, adding progression-free survival as an interim primary endpoint to support potential accelerated approval of PDS0101 in HPV16-positive head and neck cancer.
Ten63 Therapeutics announced strategic investment from Chugai Venture Fund and the Gates Foundation, bringing total funding to more than $45 million to advance its BEYOND AI drug discovery platform targeting previously undruggable proteins.
Sift Biosciences, a UC Berkeley spinout, closed an oversubscribed $3.7 million pre-seed financing to advance its AI-driven peptide immunotherapy platform targeting immunologically "cold" solid tumors.
March of Dimes awarded the 2026 Richard B Johnston Jr, MD Prize to hematologist Leonard Zon for pioneering zebrafish research that illuminated blood development in embryos and led to breakthrough treatments for genetic blood disorders in children.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07292038 |
Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors |
RECRUITING | PHASE1 |
| NCT06416267 |
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL) |
NOT_YET_RECRUITING | |
| NCT06046066 |
A Phase 1 Study of NM6603 in Advanced Solid Tumors |
TERMINATED | PHASE1 |
| NCT05299710 |
Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal) |
RECRUITING | |
| NCT04198896 |
The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC) |
COMPLETED | |
| NCT03378895 |
CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne |
COMPLETED | NA |
| NCT02734303 |
Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test |
COMPLETED | |
| NCT01646437 |
The International Polycap Study 3 (TIPS-3) |
COMPLETED | PHASE3 |
| NCT01441674 |
Animal Assisted Therapy in a Pediatric Setting |
COMPLETED | PHASE1/PHASE2 |
| NCT01295658 |
Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project |
COMPLETED |
